Back to Media center

Media Releases

Select year

Sort by

80 items found

FDA Approves New Dosing Option for CRYSVITA^® (burosumab-twza) in Adults With XLH

May 14, 2026

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

CRYSVITA^® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program

Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

January 30, 2026

Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman

December 11, 2025

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

December 8, 2025

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network^® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

November 25, 2025

Kyowa Kirin to Present New Research Highlighting Mogamulizumab’s Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting

November 18, 2025

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

November 13, 2025

Showing 80 - 1 of 8